World Economic Forum and Salesforce Empower Global Leaders With First-of-its-Kind Agentic Assistant for the 2026 Annual Meeting in Davos
15.1.2026 19:06:00 CET | Business Wire | Press Release
Salesforce (NYSE: CRM), the world’s #1 CRM, today announced the activation of the World Economic Forum’s institutional knowledge powered by Agentforce 360 to support over 3,000 of the world’s most influential leaders at the 2026 World Economic Forum Annual Meeting. The Forum has launched a new proactive, high-precision concierge app, “EVA,” built on the Agentforce 360 Platform, Salesforce’s agentic platform. EVA will empower attendees to move beyond traditional information access, with an AI agent that doesn’t just answer questions, but can reason, prioritize, and act on a leader’s behalf for the 2026 Annual Meeting.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115571119/en/
Scheduled for January 19–23 in Davos, Switzerland, this year’s event is set to be the largest meeting in the organization's history. With over 450 high-impact sessions and thousands of specialized interactions, the gap between available insight and the speed and ability to take action can be wide. By reasoning within the context of more than a decade of the World Economic Forum’s trusted institutional data, EVA acts as a force multiplier for attendees. It moves beyond chatbots and traditional FAQs, serving as a unified interface to help leaders navigate the physical event space, manage personal agendas, and facilitate networking.
Using Agentforce 360, the new app brings together AI agents, data, and people on one trusted platform to help elevate every attendee’s experience. EVA reduces manual tasks by recommending high-impact sessions, scheduling bilaterals, and generating comprehensive briefing documents in seconds. This turns what once required extensive preparation into instant, actionable intelligence.
"As we power the largest Davos ever, we're excited for every attendee to experience what it means to have an AI agent working alongside them — and how Agentforce elevates what people and organizations can achieve,” said Marc Benioff, Chair and CEO of Salesforce. “EVA, powered by Agentforce 360, is far more than a chatbot. It’s an agentic concierge, grounded in trusted data, that helps leaders move faster, prepare better, and take action. This is the Agentic Enterprise coming to life."
“We are deploying AI agents to support our staff in the event preparation, and to augment the experience for our participants,” said Børge Brende, President and CEO of the World Economic Forum. “We aren’t just optimising agendas; we are unlocking the full depth of the World Economic Forum’s institutional knowledge and putting it directly into the hands of every single attendee.”
Precision Planning: The Agent-Powered Concierge
For the 56th Annual Meeting, members can now use EVA to:
- Personalize Schedules: Recommend, book, reschedule, or cancel bilaterals and sessions on behalf of attendees.
- Navigate the Campus: Provide turn-by-turn navigation by connecting to event maps and wayfinding features.
- Prepare for Bilaterals: Create briefs with background details from the full World Economic Forum database on upcoming bilaterals and sessions, empowering participants to be as prepared as possible as they move through their day with the right information, in an easily digestible format created by the agent.
The Agentic Enterprise in Action
To reason and take action, the Agentforce 360 Platform pulls from Data 360, Salesforce’s hyperscale data engine, Agentforce Marketing, and the World Economic Forum’s event-specific knowledge articles to provide instant, contextual support. Data 360 hosts more than 500 custom objects from Salesforce CRM, forming Agentforce’s centralized knowledge base for resolving FAQs autonomously.
The deployment, led by Salesforce’s forward deployed engineering team, is part of a broader infrastructure that powers the Annual Meeting and additional events the Forum hosts throughout the year:
- Personalized Support: Agentforce Service powers customer support across web and mobile, including omnichannel assistance, advanced case management, and portals such as UpLink, the Forum's open innovation platform. Agentforce Marketing handles outreach and engagement by enabling personalized, multi-channel communications, event invitations, user journeys, and community engagement at scale.
- Connecting Data: MuleSoft securely connects the Forum’s Salesforce CRM to their third-party finance, HR, travel, and operations systems.
- Actionable Insights: Tableau transforms this data into actionable insights, tracking engagement, participation, and account activity across initiatives.
Looking ahead, the Forum plans to scale Agentforce 360 by simplifying membership registration and case management, solidifying its position as an Agentic Enterprise — one that delivers high-touch, personalized experiences at scale without increasing manual workload for staff or attendees.
About Salesforce
Salesforce helps organizations of any size become Agentic Enterprises — integrating humans, agents, apps, and data on a trusted, unified platform to unlock unprecedented growth and innovation. Visit www.salesforce.com for more information.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260115571119/en/
Contacts
PR Contact:
pr@salesforce.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom